FTI Consulting, a life science and healthcare communications practice, has named Andrew Ward as its new managing director, it was reported on Friday.
Ward joins the group from the Financial Times, where he was the pharmaceuticals correspondent for almost three years, covering the business, finance, science and regulation of the global pharmaceuticals and medical equipment industries. In the new role, Ward will be expected to broaden and deepen FTI Consulting's client base globally.
Ben Atwell, senior managing director and global head of life sciences and healthcare at FTI Consulting, said: "Andrew was one of the sector's most respected reporters during his time covering healthcare, and brings invaluable global perspective to our prestigious client base. We look forward to benefiting from his deep media experience and welcoming him to our global team of over 50 healthcare experts."
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits